We excluded 19 studies from our review because of the following reasons: Population criteria was not met in seven studies; there were no imaging/pathologic markers of steatosis or fibrosis or outcome of interest in six studies; SGLT-2 inhibitor was not used in one study; there were secondary publications of three included studies; there was incomplete data in one study; and there was still ongoing recruitment/trial in one study. This evidence concerns the gene SLC5A2 and steatosis.